Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503568 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
A Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00503568 is a Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 19 participants.
The verdict
NCT00503568, a Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells. PURPOSE: This phase I trial is studying the effects of gp96-Ig vaccine therapy in treating patients with stage III, stage IV, or relapsed non-small cell lung cancer treated with first-line chemotherapy.
Interventions
- BIOLOGICAL Ad100-gp96Ig-HLA A1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503568
The ClinicalTrials.gov registry entry for NCT00503568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ad100-gp96Ig-HLA A1 is the first listed.
NCT00503568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503568 about?
NCT00503568 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy". RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells. PURPOSE: This phase I trial is studying the effects of gp96-Ig vaccine therapy in treating patients with stage III, stage IV, or relapsed non-small cel...
What is the current status of trial NCT00503568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2007-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00503568?
The interventions under investigation include: Ad100-gp96Ig-HLA A1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00503568?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.